Current and next generation influenza vaccines: Formulation and production strategies

被引:213
|
作者
Soema, Peter C. [1 ,2 ]
Kompier, Ronald [1 ,3 ]
Amorij, Jean-Pierre [1 ]
Kersten, Gideon F. A. [1 ,2 ]
机构
[1] Intravacc Inst Translat Vaccinol, Bilthoven, Netherlands
[2] Leiden Univ, Div Drug Delivery & Technol, Leiden Acad Ctr Drug Res, NL-2300 RA Leiden, Netherlands
[3] FluConsult, Noordwijk, Netherlands
关键词
Influenza vaccines; Vaccine formulation; Vaccine production; Novel influenza vaccines; Influenza vaccine limitations; Universal influenza vaccine; HUMORAL IMMUNE-RESPONSES; CROSS-REACTIVE ANTIBODIES; SYNTHETIC PEPTIDE VACCINE; VIRUS-LIKE PARTICLE; IN-WATER EMULSION; A VIRUS; SEASONAL INFLUENZA; DOUBLE-BLIND; H5N1; VACCINE; PROTECTIVE EFFICACY;
D O I
10.1016/j.ejpb.2015.05.023
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Vaccination is the most effective method to prevent influenza infection. However, current influenza vaccines have several limitations. Relatively long production times, limited vaccine capacity, moderate efficacy in certain populations and lack of cross-reactivity are important issues that need to be addressed. We give an overview of the current status and novel developments in the landscape of influenza vaccines from an interdisciplinary point of view. The feasibility of novel vaccine concepts not only depends on immunological or clinical outcomes, but also depends on biotechnological aspects, such as formulation and production methods, which are frequently overlooked. Furthermore, the next generation of influenza vaccines is addressed, which hopefully will bring cross-reactive influenza vaccines. These developments indicate that an exciting future lies ahead in the influenza vaccine field. (C) 2015 The Authors. Published by Elsevier B.V.
引用
收藏
页码:251 / 263
页数:13
相关论文
共 50 条
  • [41] Advancing influenza vaccines: A review of next-generation candidates and their potential for global health impact
    Taaffe, Jessica
    Ostrowsky, Julia T.
    Mott, Joshua
    Goldin, Shoshanna
    Friede, Martin
    Gsell, Pierre
    Chadwick, Christopher
    VACCINE, 2024, 42 (26)
  • [42] Gene expression profiling toward the next generation safety control of influenza vaccines and adjuvants in Japan
    Momose, Haruka
    Sasaki, Eita
    Kuramitsu, Madoka
    Hamaguchi, Isao
    Mizukami, Takuo
    VACCINE, 2018, 36 (43) : 6449 - 6455
  • [43] The potential cost-effectiveness of next generation influenza vaccines in England and Wales: A modelling analysis
    Waterlow, Naomi R.
    Procter, Simon R.
    van Leeuwen, Edwin
    Radhakrishnan, Sreejith
    Jit, Mark
    Eggo, Rosalind M.
    VACCINE, 2023, 41 (41) : 6017 - 6024
  • [44] Meeting report and review: Immunological assays and correlates of protection for next-generation influenza vaccines
    Krammer, Florian
    Weir, Jerry P.
    Engelhardt, Othmar
    Katz, Jacqueline M.
    Cox, Rebecca Jane
    INFLUENZA AND OTHER RESPIRATORY VIRUSES, 2020, 14 (02) : 237 - 243
  • [45] NEXT-GENERATION OF VACCINES FOR USA
    ROBBINS, A
    LANCET, 1995, 345 (8941): : 51 - 51
  • [46] NEXT GENERATION GROUP A STREPTOCOCCAL VACCINES
    Niedermeyer, S. E.
    Penfound, T. A.
    Pullen, M. F.
    Courtney, H. S.
    Dale, J. B.
    JOURNAL OF INVESTIGATIVE MEDICINE, 2013, 61 (02) : 506 - 506
  • [47] Development of Next-Generation Vaccines
    Imai, Takashi
    VACCINES, 2022, 10 (02)
  • [48] Next-generation malarial vaccines
    Yvette van Kooyk
    Nature Materials, 2019, 18 : 94 - 96
  • [49] HIV VACCINES - THE NEXT-GENERATION
    BARNETT, SW
    KLINGER, J
    RAJASEKAR, S
    LEGG, H
    DOE, B
    SELBY, M
    WALKER, CM
    STEIMER, KS
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 1995, 11 : S135 - S135
  • [50] The next generation of vaccines for the treatment of cancer
    Long, L
    Glover, RT
    Kaufman, HL
    CURRENT OPINION IN MOLECULAR THERAPEUTICS, 1999, 1 (01) : 57 - 63